BioFuture Now: Pioneering the Future of Biopharma Breakthroughs Biotech companies turning bold science into scalable impact, from next generation therapeutics and AI native discovery engines to platforms built to expand across indications, this session offers a rare insider view of what’s coming next in healthcare and life sciences—and the stories investors and pharma will be talking about first.
10:00-10:55 am – Roof
Spotlight Panel 4B
Rewiring Minds: Breakthroughs in Brain & CNS Health Companies advancing the next generation of brain and CNS therapeutics, from novel small molecules and biologics to advanced gene, cell, and RNA based approaches, will showcase drug candidates and platforms targeting neurological, neurodegenerative, and psychiatric conditions.
11:00-11:55 am – Roof
Seed Pitch Doctor Presentations
Innovative seed companies present a 5-minute, high-impact introduction & company presentation with a panel of investors and industry leaders (“Pitch Doctors") offering real-time, actionable feedback.
12:00-1:00 pm – 2nd Floor
Networking Lunch
1:00 pm – 2nd Floor
One-to-One Meetings
1:00-1:55 pm – Roof
“Big Think" Plenary Session
From Seed to Scale: How Will the Next Wave of Biotech Get Financed The next generation of breakthrough biotech companies is being built in today’s seed market. However, with capital now flowing to later stage companies with de-risked assets, what tactics are early-stage companies are using to fund their operations.
2:00-2:55 pm – 12th Floor
Dialogue 2A
Made in the USA
2:00-2:55 pm – Roof
Dialogue 2B
3:00-3:55 pm – 12th Floor
Dialogue 3A
China: A Global Biotech Player Regulatory reform, improved access to capital, a fast-accelerating innovation ecosystem and the ability to cost-effectively conduct clinical trials are propelling China to the forefront of global biotech growth.
3:00-3:55 pm – Roof
Dialogue 3B
4:00-4:55 pm – Roof
“Fireside Chat " Closing Session
Leveraging Deep Disease Area Expertise to Bring Transformational Medicines to Patients
John Reed, MD, PhD, EVP, Innovative Medicine, R&D, Johnson & Johnson